TriangleNCT00365053 · OUTCOME
Histone Acetylation by IHC and Western Blotting
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- At baseline and at 4 hours after last dose of PXD101 on day 5
What was measured
Summarized with contingency tables or scatterplots, and with quantitative measures of agreement.
Analysis population: IHC data were not collected.
Groups in this outcome
Treatment (Belinostat)
Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. belinostat: Given IV laboratory biomarker analysis: Correlative studies
| Group | Source count |
|---|---|
| Treatment (Belinostat) | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Summarized with contingency tables or scatterplots, and with quantitative measures of agreement.
- groups
- description
- Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. belinostat: Given IV laboratory biomarker analysis: Correlative studies
- id
- OG000
- title
- Treatment (Belinostat)
- population Description
- IHC data were not collected.
- reporting Status
- POSTED
- time Frame
- At baseline and at 4 hours after last dose of PXD101 on day 5
- title
- Histone Acetylation by IHC and Western Blotting
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice